C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, ...

C3.ai (AI 5.72%) developed a portfolio of 40 ready-made AI software applications that businesses can customize to suit their needs. These apps serve as a shortcut to AI adoption, and while they have ...

C3.ai remains a hold here, due to its persistent lack of profitable growth despite the AI SaaS sector boom, as similarly observed in its underwhelming Rule of -52.1% performance. Recent federal ...

C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage. The efficacy and safety of ...

Three weeks ago, C3.ai (NYSE:AI) released preliminary fiscal Q1 2026 financial results, sending its stock plummeting 14% as investors recoiled from lackluster performance. Yesterday, the company ...

Artificial intelligence software company C3 AI Inc.’s stock was battered and bruised in extended trading, down more than 10% after it delivered disappointing financial results and a weak outlook. That ...

C3.ai has carved out a unique position as a pure-play enterprise AI platform company. It doesn't build flashy consumer chatbots. Instead, it helps large organizations deploy AI across real-world ...

Google announced a new multi-vector retrieval algorithm called MUVERA that speeds up retrieval and ranking, and improves accuracy. The algorithm can be used for search, recommender systems (like ...

C3.ai provides AI-driven solutions to the Department of Defense (DoD) and the U.S. Army. It has delivered custom AI solutions to the National Science Foundation and the Marine Corps. C3.ai secured a ...

Malaria remains one of the most devastating diseases worldwide. Blocking malaria transmission is considered a promising strategy for controlling and potentially eliminating the disease. In this study, ...